homepage image

Rethinking
Brain Health

MindMed works to improve patient outcomes through our pipeline of novel drug candidates and digital therapeutics.

12/1/22

MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference

We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.

Anxiety
21%
1-year prevalence of anxiety disorders in the US
ADHD
4.4%
Estimated prevalence among US adults
Autism Spectrum Disorder
$461B
Economic cost of ASD in the US predicted by 2025

A Global Leader in Brain Health

MindMed uses industry-leading drug development expertise in its mission to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.

Research & Development Pipeline

Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action

Explore MindMed’s R&D Programs to learn more about the opportunities that exist to advance novel treatments for a wide range of brain health disorders.